(Q36697928)

15 August 2017

1 reference

title

Treatment of skeletal disease in breast cancer with clodronate (English)

1 reference

15 August 2017

1 reference

https://api.crossref.org/works/10.1016/8756-3282(91)90063-O

7 November 2022

author name string

McCloskey EV

5

1 reference

15 August 2017

A. H. Paterson

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1720012

7 November 2022

D. S. Ernst

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1720012

7 November 2022

T. J. Powles

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1720012

7 November 2022

S. Ashley

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1720012

7 November 2022

E. V. McCloskey

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1720012

7 November 2022

J. A. Kanis

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1720012

7 November 2022

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=1720012

7 November 2022

publication date

1 January 1991

1 reference

full work available at URL

15 August 2017

https://api.elsevier.com/content/article/PII:875632829190063O?httpAccept=text/xml

1 reference

https://api.crossref.org/works/10.1016/8756-3282(91)90063-O

https://api.elsevier.com/content/article/PII:875632829190063O?httpAccept=text/plain

7 November 2022

1 reference

https://api.crossref.org/works/10.1016/8756-3282(91)90063-O

7 November 2022

1 reference

15 August 2017

volume

12 Suppl 1

1 reference

15 August 2017

page(s)

S25-30

1 reference

Clodronate therapy of metastatic bone disease in patients with prostatic carcinoma

15 August 2017

cites work

1

1 reference

https://api.crossref.org/works/10.1016/8756-3282(91)90063-O

Substance P- and CGRP-immunoreactive nerves in bone

7 November 2022

4

1 reference

https://api.crossref.org/works/10.1016/8756-3282(91)90063-O

Neuropeptide Y-, tyrosine hydroxylase- and vasoactive intestinal polypeptide-immunoreactive nerves in bone and surrounding tissues.

7 November 2022

5

1 reference

https://api.crossref.org/works/10.1016/8756-3282(91)90063-O

The management of pathological fracture of the major long bones from metastatic cancer

7 November 2022

6

1 reference

https://api.crossref.org/works/10.1016/8756-3282(91)90063-O

Long-Term Effects of Dichloromethylene Diphosphonate (Cl2 DP) on skeletal Lesions in Multiple Myeloma

7 November 2022

7

1 reference

https://api.crossref.org/works/10.1016/8756-3282(91)90063-O

Treatment of skeletal disease in breast cancer: a controlled clodronate trial

7 November 2022

8

1 reference

https://api.crossref.org/works/10.1016/8756-3282(91)90063-O

Cancer of the breast: the past decade (first of two parts).

7 November 2022

11

1 reference

https://api.crossref.org/works/10.1016/8756-3282(91)90063-O

Stimulation of bone resorption in vitro by synthetic transforming growth factor-alpha

7 November 2022

12

1 reference

https://api.crossref.org/works/10.1016/8756-3282(91)90063-O

Comparison of two parenteral diphosphonates in hypercalcemia of malignancy

7 November 2022

13

1 reference

https://api.crossref.org/works/10.1016/8756-3282(91)90063-O

Use of diphosphonates in hypercalcaemia due to malignancy

7 November 2022

16

1 reference

https://api.crossref.org/works/10.1016/8756-3282(91)90063-O

Comparative effects of intravenous diphosphonates on calcium and skeletal metabolism in man

7 November 2022

17

1 reference

https://api.crossref.org/works/10.1016/8756-3282(91)90063-O

Ectopic production of parathyroid hormone by carcinoma of the breast

7 November 2022

18

1 reference

https://api.crossref.org/works/10.1016/8756-3282(91)90063-O

The hypercalcemia of malignancy

7 November 2022

21

1 reference

https://api.crossref.org/works/10.1016/8756-3282(91)90063-O

Chemotactic Responses of Tumor Cells to Products of Resorbing Bone

7 November 2022

23

1 reference

https://api.crossref.org/works/10.1016/8756-3282(91)90063-O

The use of dichloromethylene diphosphonate for the management of hypercalcaemia in multiple myeloma

7 November 2022

25

1 reference

https://api.crossref.org/works/10.1016/8756-3282(91)90063-O

Case report: Chronic lymphocytic leukemia and hypercalcemia: Treatment with dichloromethylene diphosphonate

7 November 2022

28

1 reference

https://api.crossref.org/works/10.1016/8756-3282(91)90063-O

Effects of dichloromethylene diphosphonate in women with breast carcinoma metastatic to the skeleton

7 November 2022

29

1 reference

https://api.crossref.org/works/10.1016/8756-3282(91)90063-O

A randomized trial of two dose levels of cyclophosphamide, methotrexate, and fluorouracil chemotherapy for patients with metastatic breast cancer.

7 November 2022

30

1 reference

https://api.crossref.org/works/10.1016/8756-3282(91)90063-O

Clodronate. A randomized study in the treatment of cancer-related hypercalcemia

7 November 2022

32

1 reference

https://api.crossref.org/works/10.1016/8756-3282(91)90063-O

7 November 2022

Identifiers

1 reference

15 August 2017

1 reference